Your browser doesn't support javascript.
loading
miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
Sewastianik, Tomasz; Straubhaar, Juerg R; Zhao, Jian-Jun; Samur, Mehmet K; Adler, Keith; Tanton, Helen E; Shanmugam, Vignesh; Nadeem, Omar; Dennis, Peter S; Pillai, Vinodh; Wang, Jianli; Jiang, Meng; Lin, Jianhong; Huang, Ying; Brooks, Daniel; Bouxsein, Mary; Dorfman, David M; Pinkus, Geraldine S; Robbiani, Davide F; Ghobrial, Irene M; Budnik, Bogdan; Jarolim, Petr; Munshi, Nikhil C; Anderson, Kenneth C; Carrasco, Ruben D.
Affiliation
  • Sewastianik T; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Straubhaar JR; Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Zhao JJ; FAS Informatics, Harvard University, Cambridge, MA.
  • Samur MK; Department of Medical Oncology and.
  • Adler K; Department of Medical Oncology and.
  • Tanton HE; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Shanmugam V; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA.
  • Nadeem O; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Dennis PS; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Pillai V; Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
  • Wang J; Department of Medical Oncology and.
  • Jiang M; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Lin J; Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
  • Huang Y; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Brooks D; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Bouxsein M; Department of Medical Oncology and.
  • Dorfman DM; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Pinkus GS; Center for Advanced Orthopedic Studies, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Robbiani DF; Center for Advanced Orthopedic Studies, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Ghobrial IM; Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
  • Budnik B; Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
  • Jarolim P; Laboratory of Molecular Immunology, Rockefeller University, New York, NY.
  • Munshi NC; Department of Medical Oncology and.
  • Anderson KC; Mass Spectrometry and Proteomics Resource Laboratory, FAS Division of Science, Harvard University, Cambridge, MA; and.
  • Carrasco RD; Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Blood ; 137(14): 1905-1919, 2021 04 08.
Article in En | MEDLINE | ID: mdl-33751108
ABSTRACT
Chromosome 13q deletion [del(13q)], harboring the miR-15a/16-1 cluster, is one of the most common genetic alterations in mature B-cell malignancies, which originate from germinal center (GC) and post-GC B cells. Moreover, miR-15a/16 expression is frequently reduced in lymphoma and multiple myeloma (MM) cells without del(13q), suggesting important tumor-suppressor activity. However, the role of miR-15a/16-1 in B-cell activation and initiation of mature B-cell neoplasms remains to be determined. We show that conditional deletion of the miR-15a/16-1 cluster in murine GC B cells induces moderate but widespread molecular and functional changes including an increased number of GC B cells, percentage of dark zone B cells, and maturation into plasma cells. With time, this leads to development of mature B-cell neoplasms resembling human extramedullary plasmacytoma (EP) as well as follicular and diffuse large B-cell lymphomas. The indolent nature and lack of bone marrow involvement of EP in our murine model resembles human primary EP rather than MM that has progressed to extramedullary disease. We corroborate human primary EP having low levels of miR-15a/16 expression, with del(13q) being the most common genetic loss. Additionally, we show that, although the mutational profile of human EP is similar to MM, there are some exceptions such as the low frequency of hyperdiploidy in EP, which could account for different disease presentation. Taken together, our studies highlight the significant role of the miR-15a/16-1 cluster in the regulation of the GC reaction and its fundamental context-dependent tumor-suppression function in plasma cell and B-cell malignancies.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / MicroRNAs / Neoplasms, Plasma Cell Limits: Animals / Humans Language: En Journal: Blood Year: 2021 Type: Article Affiliation country: Morocco

Full text: 1 Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / MicroRNAs / Neoplasms, Plasma Cell Limits: Animals / Humans Language: En Journal: Blood Year: 2021 Type: Article Affiliation country: Morocco